Drug intelligence / Profile preview

HH-012

Development stage: Unknown
Lead developer: Huahui Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HH-012 is a monoclonal antibody developed by Huahui Health that targets a novel coinhibitory receptor. It is currently in Phase I clinical trials for the treatment of solid tumors. The specific mechanism of action and molecular target have not been publicly disclosed, but it is positioned as an immuno-oncology agent designed to modulate immune checkpoints and enhance anti-tumor immune responses[1][4]. The drug represents part of Huahui Health's pipeline focused on innovative therapies for oncology.

Targets

Checkpoint (Immune checkpoints)

Beyond the preview

Go deeper on HH-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH-012.

Explore the full profile